Literature DB >> 35786957

Challenges in the Management of Patients With HER2-Amplified Colorectal Cancer.

Timothy J Brown1,2, Ryan C Massa1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35786957      PMCID： PMC9377689          DOI： 10.1200/OP.22.00361

Source DB:  PubMed          Journal:  JCO Oncol Pract        ISSN： 2688-1527


× No keyword cloud information.
  11 in total

1.  Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Al B Benson; Alan P Venook; Mahmoud M Al-Hawary; Mustafa A Arain; Yi-Jen Chen; Kristen K Ciombor; Stacey Cohen; Harry S Cooper; Dustin Deming; Linda Farkas; Ignacio Garrido-Laguna; Jean L Grem; Andrew Gunn; J Randolph Hecht; Sarah Hoffe; Joleen Hubbard; Steven Hunt; Kimberly L Johung; Natalie Kirilcuk; Smitha Krishnamurthi; Wells A Messersmith; Jeffrey Meyerhardt; Eric D Miller; Mary F Mulcahy; Steven Nurkin; Michael J Overman; Aparna Parikh; Hitendra Patel; Katrina Pedersen; Leonard Saltz; Charles Schneider; David Shibata; John M Skibber; Constantinos T Sofocleous; Elena M Stoffel; Eden Stotsky-Himelfarb; Christopher G Willett; Kristina M Gregory; Lisa A Gurski
Journal:  J Natl Compr Canc Netw       Date:  2021-03-02       Impact factor: 11.908

2.  Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.

Authors:  Andrea Sartore-Bianchi; Livio Trusolino; Cosimo Martino; Katia Bencardino; Sara Lonardi; Francesca Bergamo; Vittorina Zagonel; Francesco Leone; Ilaria Depetris; Erika Martinelli; Teresa Troiani; Fortunato Ciardiello; Patrizia Racca; Andrea Bertotti; Giulia Siravegna; Valter Torri; Alessio Amatu; Silvia Ghezzi; Giovanna Marrapese; Laura Palmeri; Emanuele Valtorta; Andrea Cassingena; Calogero Lauricella; Angelo Vanzulli; Daniele Regge; Silvio Veronese; Paolo M Comoglio; Alberto Bardelli; Silvia Marsoni; Salvatore Siena
Journal:  Lancet Oncol       Date:  2016-04-20       Impact factor: 41.316

3.  Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.

Authors:  Funda Meric-Bernstam; Herbert Hurwitz; Kanwal Pratap Singh Raghav; Robert R McWilliams; Marwan Fakih; Ari VanderWalde; Charles Swanton; Razelle Kurzrock; Howard Burris; Christopher Sweeney; Ron Bose; David R Spigel; Mary S Beattie; Steven Blotner; Alyssa Stone; Katja Schulze; Vaikunth Cuchelkar; John Hainsworth
Journal:  Lancet Oncol       Date:  2019-03-08       Impact factor: 41.316

4.  HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer.

Authors:  Andrea Sartore-Bianchi; Alessio Amatu; Luca Porcu; Silvia Ghezzi; Sara Lonardi; Francesco Leone; Francesca Bergamo; Elisabetta Fenocchio; Erika Martinelli; Beatrice Borelli; Federica Tosi; Patrizia Racca; Emanuele Valtorta; Emanuela Bonoldi; Cosimo Martino; Caterina Vaghi; Giovanna Marrapese; Fortunato Ciardiello; Vittorina Zagonel; Alberto Bardelli; Livio Trusolino; Valter Torri; Silvia Marsoni; Salvatore Siena
Journal:  Oncologist       Date:  2019-04-05

Review 5.  Human Epidermal Growth Factor Receptor 2-Targeting Approaches for Colorectal Cancer: Clinical Implications of Novel Treatments and Future Therapeutic Avenues.

Authors:  Canan Karan; Elaine Tan; Humaira Sarfraz; Todd C Knepper; Christine M Walko; Seth Felder; Richard Kim; Ibrahim Halil Sahin
Journal:  JCO Oncol Pract       Date:  2022-05-25

6.  Assessment of a HER2 scoring system for colorectal cancer: results from a validation study.

Authors:  Emanuele Valtorta; Cosimo Martino; Andrea Sartore-Bianchi; Frédérique Penaullt-Llorca; Giuseppe Viale; Mauro Risio; Massimo Rugge; Walter Grigioni; Katia Bencardino; Sara Lonardi; Vittorina Zagonel; Francesco Leone; Johannes Noe; Fortunato Ciardiello; Carmine Pinto; Roberto Labianca; Stefania Mosconi; Claudio Graiff; Giuseppe Aprile; Barbara Frau; Carlo Garufi; Fotios Loupakis; Patrizia Racca; Giuseppe Tonini; Calogero Lauricella; Silvio Veronese; Mauro Truini; Salvatore Siena; Silvia Marsoni; Marcello Gambacorta
Journal:  Mod Pathol       Date:  2015-10-09       Impact factor: 7.842

7.  Nudge Units to Improve the Delivery of Health Care.

Authors:  Mitesh S Patel; Kevin G Volpp; David A Asch
Journal:  N Engl J Med       Date:  2018-01-18       Impact factor: 91.245

Review 8.  Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.

Authors:  S Siena; A Sartore-Bianchi; S Marsoni; H I Hurwitz; S J McCall; F Penault-Llorca; S Srock; A Bardelli; L Trusolino
Journal:  Ann Oncol       Date:  2018-05-01       Impact factor: 32.976

9.  Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial.

Authors:  Yoshiaki Nakamura; Wataru Okamoto; Takeshi Kato; Taito Esaki; Ken Kato; Yoshito Komatsu; Satoshi Yuki; Toshiki Masuishi; Tomohiro Nishina; Hiromichi Ebi; Kentaro Sawada; Hiroya Taniguchi; Nozomu Fuse; Shogo Nomura; Makoto Fukui; Seiko Matsuda; Yasutoshi Sakamoto; Hiroshi Uchigata; Kana Kitajima; Naomi Kuramoto; Takashi Asakawa; Steve Olsen; Justin I Odegaard; Akihiro Sato; Satoshi Fujii; Atsushi Ohtsu; Takayuki Yoshino
Journal:  Nat Med       Date:  2021-11-11       Impact factor: 53.440

10.  HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer.

Authors:  Naoki Takegawa; Kimio Yonesaka; Kazuko Sakai; Hiroto Ueda; Satomi Watanabe; Yoshikane Nonagase; Tatsuya Okuno; Masayuki Takeda; Osamu Maenishi; Junji Tsurutani; Taroh Satoh; Isamu Okamoto; Kazuto Nishio; Takao Tamura; Kazuhiko Nakagawa
Journal:  Oncotarget       Date:  2016-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.